Mr. Boye is co-founder and Chief Technology Officer of Atsena Therapeutics. He is also an Associate Scientist of Pediatrics and Associate Director of the Powell Gene Therapy Center at the University of Florida. His research on AAV and ocular gene therapy spans 20 years and over 110 publications. He has focused primarily on the utilization of recombinant AAV as a gene therapy vector for the treatment of retinal disease and has designed AAV vectors used to establish proof of concept in animal models of autosomal recessive retinitis pigmentosa, X-linked retinitis pigmentosa, Achromatopsia, Bardet-Biedl syndrome, Usher syndrome and multiple forms of Leber congenital amaurosis (LCA). Many of these gene therapies have since been applied in the clinic. A secondary focus of his research is synthetic virology. Using a combination of directed evolution and rational design, he aims optimize the AAV capsid and genome to improve its performance and safety. He is a prolific inventor of AAV-related technologies, holding 10 awarded and eight pending patents.
Sanford L. BoyeCo-founder and Chief Technology Officer, Atsena Therapeutics; Associate Scientist and Director, Powell Gene Therapy Center at the University of Florida
